For instance, Della Corte et al. [37], found metformin potentiates the anti-tumor activity of MEK inhibitors (selumetinic and pimasertib) in human LKB1-wilde-type non-small cell lung cancer (NSCLC cell line) through glioma-associated oncogene homolog 1 (GLI1) downregulation and by reducing transcription of metalloproteinase-2 and 9 (MMP-2 and MMP-9). The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.